Skip to main content
. Author manuscript; available in PMC: 2012 Jun 15.
Published in final edited form as: Cancer Res. 2011 Apr 20;71(12):4314–4324. doi: 10.1158/0008-5472.CAN-11-0051

Figure 7.

Figure 7

HOXC9 inhibits the proliferation and tumorigenicity of SK-N-AS cells. A, ChIP-qPCR analysis of H3K4me3 and H3K27me3 levels at the HOXC9 promoter in BE(2)-C and SK-N-AS cells either untreated or treated with RA for 24 hours (error bars, s.d., n=3). Percentage of input indicates bound/input × 100. B, Proliferation assays of SK-N- AS cells with or without HOXC9 induction (error bars, s.d., n=4). C, qRT-PCR analysis of RET mRNA levels in SK-N-AS cells with or without HOXC9 induction for 3 days (error bars, s.d., n=3). D, Scatter plot of xenograft tumor weight with horizontal lines indicating the mean per group. Data were analyzed with two-tailed Student’s t-test with the p value indicated.